Cationic anti-microbial peptides and methods of use thereof
Described herein are methods of detecting a wound infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with a cationic anti-microbial peptide that is degradable by an enzyme produced and/or secreted by a microorganism, and detecting degradation or the absence of degradation of the peptide, as an indicator of the presence or absence of the enzyme in the sample, and thus indicative of the presence or absence of a microorganism in the sample. The present invention also features a biosensor for detecting the presence or absence of a microorganism in a sample.
1. A method for detecting the presence or absence of a proteinase in a sample, wherein the presence of the proteinase is indicative of the presence of bacteria selected from the group consisting of Streptococcus pyogenes, Pseudomonas aeruginosa, Enterococcus faecalis, Proteus mirabilis and combinations thereof, in the sample, wherein the method comprises the steps of:
(a) contacting the sample with a detectably labeled substrate, wherein the substrate comprises a cationic anti-microbial peptide variant consisting of an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1 or SEQ ID NO:2 over the entire length of SEQ ID NO: 1 or SEQ ID NO:2, respectively, wherein said peptide variant does not comprise SEQ ID NO:3, and wherein the peptide variant is degradable by a proteinase produced and/or secreted by said bacteria, under conditions that result in the degradation of the peptide variant by the proteinase, wherein degradation of the peptide variant results in a detectable signal; and
(b) detecting the resulting signal indicative of the peptide variant degradation, wherein degradation of the peptide variant indicates the presence of the bacterial proteinase in the sample.
2. The method of claim 1 , wherein said sample is selected from the group consisting of a wound surface on a subject and a body fluid.
3. The method of claim 1 , wherein said substrate is on a solid support.
4. The method of claim 3 , wherein the solid support comprises a material free of microbial contaminants prior to contacting the sample with the detectably labeled substrate.
5. The method of claim 3 , wherein said solid support is selected from the group consisting of a wound dressing, a container for holding body fluids, a disk, a scope, a filter, a lens, foam, cloth, paper, a suture, and a swab.
6. The method of claim 5 , wherein said container for holding body fluids is selected from the group consisting of a urine collection bag, a blood collection bag, plasma collection bag, a test tube, a catheter, and a well of a microplate.
7. The method of claim 2 wherein the sample is wound fluid and detection of the presence of the proteinase in wound fluid is indicative of the presence of said bacteria in the wound.
8. The method of claim 7 wherein the presence of said bacteria in the wound fluid is an indication of a wound infection.
9. The method of claim 2 wherein the body fluid is selected from the group consisting of: blood, urine and sputum.
10. The method of claim 9 wherein the presence of the proteinase in the body fluid is indicative of the presence of said bacteria in the blood, urine or sputum.
11. A method comprising:
(a) contacting a body fluid with a detectably labeled substrate, wherein the substrate comprises a cationic anti-microbial peptide variant consisting of an amino add sequence having at least 90% sequence identity with SEQ ID NO: 1 or SEQ ID NO:2 over the entire length of SEQ ID NO: 1 or SEQ ID NO:2, respectively, wherein said peptide variant does not comprise SEQ ID NO:3, which is degradable by a proteinase produced and/or secreted by one or more pathogenic bacteria species, under conditions that result in the degradation of the peptide variant by the proteinase, wherein degradation of the peptide variant results in a detectable signal; and
(b) detecting the resulting signal.
12. The method of claim 11 , wherein the body fluid is selected from the group consisting of wound fluid, blood, urine and sputum.
13. The method of claim 12 , wherein the body fluid is wound fluid.
14. The method of claim 11 , wherein the pathogenic bacteria species is selected from the group consisting of Streptococcus pyogenes, Pseudomonas aeruginosa, Enterococcus faecalis, Proteus mirabilis and combinations thereof.
15. The method of claim 14 , wherein the pathogenic bacteria species is Streptococcus pyogenes.
16. A method comprising:
(a) contacting a sample contacted by body fluid with a detectably labeled substrate, wherein the substrate comprises a cationic anti-microbial peptide variant consisting of an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1 or SEQ ID NO:2 over the entire length of SEQ ID NO:1 or SEQ ID NO:2, respectively, wherein said peptide variant does not comprise SEQ ID NO:3 which is degradable by a proteinase produced and/or secreted by one or more pathogenic bacteria species, under conditions that result in the degradation of the peptide variant by the proteinase, wherein degradation of the peptide variant results in a detectable signal; and
(b) detecting the resulting signal.
17. The method of claim 16 , wherein the body fluid is selected from the group consisting of wound fluid, blood, urine and sputum.
18. The method of claim 16 , wherein the pathogenic bacteria species is selected from the group consisting of Streptococcus pyogenes, Pseudomonas aeruginosa, Enterococcus faecalis, Proteus mirabilis and combinations thereof,
19. The method of claim 18 , wherein the pathogenic bacteria species is Streptococcus pyogenes.
20. The method of claim 16 , wherein the sample is selected from the group consisting of a wound dressing, a container for holding body fluids, a disk, a scope, a filter, a lens, foam, cloth, paper, a suture, and a swab.